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SARS-CoV2 infection enters via the nose, and, following aspiration to the lower respiratory 
tract, may then rapidly involve the lungs, resulting in severe hypoxic pneumonia. In the later 
stage of COVID-19 there is also a cytokine-mediated hyper-inflammatory response and 
coagulopathy, which in many respects simulates a viral induced multi-organ autoimmune 
response 1 (Figure). Patients who tend to fare worse with more severe outcomes are males, 
elderly, smokers, Black and Asian people, those with obesity, along with the presence of 
comorbidities such as diabetes, hypertension, chronic heart, lung and kidney disease, 
dementia, neoplasia, and immunosuppression2.  
 
Along with these various risk factors, much interest has centred around trying to identify 
biomarkers to predict which patients admitted to hospital with severe COVID-19 are most 
likely to rapidly deteriorate and require intensive care with invasive ventilation. A ratio for 
arterial oxygen tension (PaO2) or oxygen saturation (SaO2) to the fraction of inspired 
oxygen (FiO2), referred to as the P/F or S/F ratio respectively, of less than 300 is used to 
define the presence of respiratory failure, while a ratio of less than 100 is indicative of severe 
acute respiratory distress syndrome (ARDS). Some cases of ARDS with COVID-19 may be 
accompanied by the development of secondary hemophagocytic lymphohistiocytosis 
(Figure).  
 
Biomarkers of hyperinflammation in COVID-19 include C reactive protein (CRP), interleukin-
6 (IL6), ferritin, D-dimers, lactate dehydrogenase (LDH), procalcitonin, lymphopenia, and 
thrombocytopenia1. Since IL6 induces hepatic synthesis of CRP, it would be expected that 
they would track together as makers of systemic inflammation 3. This in turn begs the 
question as to whether circulating levels of IL6 and CRP are associated with worse 
outcomes in severe COVID-19. A retrospective cohort evaluation among 140 patients with 
COVID-19 reported IL6 levels greater than 32.1 pg/ml and CRP greater than 41.8 mg/l were 
more likely to be related to severe disease, with respective hazard ratios of 2.4 (95%CI 1.06-
5.3) and 4.4 (95%CI 1.9-10.3) 4. Another study of 127 patients with COVID-19 found that IL6 
was superior to other inflammatory markers in identifying severe disease in terms of the area 
under the receiver operating curve (AUC) being 0.84 with a sensitivity of 88% and specificity 
of 75%5. Furthermore, when IL-6 was combined with CRP and hypertension, the AUC 
improved to 0.90 with sensitivity of 100% and specificity of 66%. However, relatively few of 
the patients in either of these studies had severe disease, in particular with regard to 
patients requiring invasive ventilation A more informative study from Germany in a single 
University-based hospital setting studied two separate cohorts comprising 89 patients with 
severe hypoxic COVID-19 pneumonia, evaluating biomarkers on admission and during the 
course of the illness, with 36% requiring invasive ventilation6. A cut off value for IL6 of 49 
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pg/ml on admission had an AUC of 0.89, while a cut off of 65 pg/ml for maximal levels had 
an AUC of 0.93, in regard to predicting the need for invasive ventilation. Corresponding cut-
off and AUC values for CRP were 32 mg/ml and 0.83 on admission and 97mg/ml and 0.85 
for maximal levels. The cut offs for maximal IL-6 and CRP levels in the validation cohort of 
49 patients both correctly classified 80% of patients regarding their risk of respiratory failure, 
whereas corresponding values at presentation were 71% and 76%. Moreover, in the 
combined cohort, patients reached the cut-off for IL6 greater than 65 pg/ml and CRP greater 
than 97 mg/L at a median of 23.2 and 15.7 hours prior to intubation.  
 
In this issue of the journal, Vultaggio and coworkers from Italy have taken the biomarker 
analysis a step further in a cohort of 208 patients with severe COVID-19 in a single 
University-based hospital setting, with clinical deterioration occurring in 63 cases, of whom 
39 were intubated and 16 died7. Notably 45 patients worsened within 3 days of admission. 
The highest AUC values for predicting 3 day worsening were observed for S/F ratio (0.81) 
followed by IL6 (0.78), CRP and LDH (both 0.76) and ferritin (0.70). Combining IL6, CRP, 
and S/F ratio in a composite score resulted in an improved AUC value of 0.88. Moreover, the 
composite score also exhibited good performance for predicting deterioration over 21 days 
or death, with AUC values of 0.83 and 0.82 respectively. The authors duly acknowledged the 
limitations of the study due to the relatively small sample size as well as the need for further 
validation of the composite score outside of a University-based hospital setting.  
 
Taken together, these findings may have some important potential implications in the 
management of patients with severe COVID-19. Firstly, raised IL6 or CRP on initial 
presentation or rising levels during the course of the illness in conjunction with falling S/F or 
P/F ratio clearly indicates a need to escalate treatment. One such therapeutic intervention 
might be the use of systemic corticosteroids, which non-selectively suppress pro-
inflammatory cytokines. The preliminary results from the United Kingdom RECOVERY trial 
in severe COVID-19 showed that, compared to 4321 patients receiving usual care, treatment 
with dexamethasone 6mg for 10 days in 2014 patients was associated with a 35% relative 
reduction in deaths after 28 days in ventilated patients and a 20% relative reduction in 
patients requiring oxygenation alone 8. For patients being ventilated or oxygenated, this 
translated into treating 8 or 25 cases respectively with dexamethasone in order to prevent 
one death. It will be pertinent to know if reductions in mortality with dexamethasone were 
more pronounced in patients who had raised levels of CRP or IL6 or a reduced P/F ratio, 
either alone or combination.  
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We propose that a tailored biomarker approach towards endotype-guided pharmacotherapy 
might in turn result in improved outcomes in patients with severe COVID-19. For example, 
one strategy in such patients might be to escalate therapy in terms of selectively inhibiting 
pro-inflammatory cytokines. In this regard, we await to see the full results from randomised 
controlled trials with anti-IL6 agents, as preliminary data with sarilumab versus placebo 
reported marked reductions in CRP, which appeared to be disconnected from improvements 
in clinical outcomes in severe COVID-199. Another approach involved selectively inhibiting 
IL1β with the IL1 antagonist anakinra, which in a small cohort study reduced the need for 
invasive ventilation and death in patients with severe COVID-19 10. Perhaps, as is the case 
with dexamethasone, one might expect to see the biggest improvements with selective 
cytokine blockers in those patients with more critical disease where hyperinflammation and 
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Figure Legend  
SARS-CoV-2 infection enters the respiratory tract via the nose, which, in susceptible 
individuals, is followed by development of COVID-19 pneumonia with hypoxaemia and need 
for oxygenation. This may be accompanied by a profound cytokine cascade involving IL6 
stimulating hepatic synthesis of CRP. Cytokine activation in turn results in ARDS and 
coagulopathy with release of D-dimers and, in some cases, secondary hemophagocytic 
lymphohistiocytosis. 

